ARCHIVES

Phase III Tecemotide Trial Fails OS Endpoint; Second Trial Planned After Subgroup Analysis

This article is from The Cancer Letter archive.

Vol. 36 No. 12 | December 27, 2013

Download PDF Visit The Full Archive

Related Articles

NCI Cancer Bulletin publicized board’s resignation over liability concerns.

April 16, 2004

Michelle Le Beau named director of University of Chicago Cancer Research Center.

May 7, 2004

Young Elected ACS President, Von eschenback Pres.-Elect.

November 9, 2001

ODAC To Review Taxol Nov. 16; NCI, Bristol to Discuss Pricing

October 23, 1992

Surgery Without Radiation Found Inadequate for DCIS

December 26, 2003

Report Criticizes NIH Grant Review

June 16, 1995